TABLE 3.
Comparison of meta-analyses of daptomycin versus linezolid for VRE BSIsb
| Authors (reference) | No. of studies | Daily dose(s) |
Primary outcome | Findings | |
|---|---|---|---|---|---|
| Daptomycin (mg/kg/day) | Linezolid (mg/day) | ||||
| Shi et al. (90) | 22 | All patients, 3.4–11.5 | 1,200 (n = 10), NR (n = 12) | Mortality as described in individual studies | All patients, ↑ mortality for daptomycin (OR = 1.27 [95% CI, 0.99–1.63]; I2 = 42.9%) |
| Subgroup analysis, >6 (HD) (n = 3); irrespective of dosea (n = 18) | Subgroup analysis, comparable mortality when HD daptomycin was used (OR = 0.92 [95% CI, 0.46–1.84]; I2 = 49.4%) | ||||
| Zhao et al. (89) | 11 | Median, 6 (n = 9); median, 6.1 (n = 1); mean, 7.4 (n = 1); range, 6–11.5 | 1,200 (n = 8), NR (n = 3) | Crude overall mortality | Similar mortality rates (RR = 1.07 [95% CI, 0.83–1.37] [P = 0.61]; I2 = 48%) |
| Chuang et al. (133) | 13 | Median, 6 (n = 4); median, 5.5 (n = 1); mean, 6.4 (n = 1); 6 (n = 2); NR (n = 5) | 1,200 (n = 7), NR (n = 6) | Mortality | ↑ mortality for daptomycin (OR = 1.43 [95% CI, 1.09–1.86] [P = 0.009]; I2 = 0%) |
| Balli et al. (134) | 10 | Median, 6 (n = 6); median, 5.5 (n = 1); NR (n = 3) | 1,200 (n = 6), NR (n = 4) | Mortality (30-day all-cause) | ↑ mortality for daptomycin (OR = 1.61 [95% CI, 1.08–2.40]; fixed-effects model [heterogeneity P = 0.42]) |
| Whang et al. (132) | 9 | Usual dose, 6; range, 3.4–10.4 | 1,200 (n = 4), NR (n = 5) | Mortality as defined by the study investigators | ↑ survival with linezolid (OR = 1.3 [95% CI, 1.0–1.8]; I2 = 0 [P = 0.053]) |
a
Studies that did not provide dose data or did not meet the criteria for high-dose daptomycin dosing.
b
HD, high dose; NR, not reported; RR, risk ratio; OR, odds ratio; CI, confidence interval.